학술논문

INTERIM SINGLE-AGENT SAFETY AND ANTI-TUMOR ACTIVITY FROM DOSE ESCALATION PHASE OF ABILITY STUDY ON MDNA11, A LONG-ACTING BETA-ONLY IL-2 AGONIST
Document Type
Journal
Source
JOURNAL FOR IMMUNOTHERAPY OF CANCER; NOV 2022, 10 pA777-pA777, 1p. Supplement: 2
Subject
Language
English
ISSN
20511426